MyoKardia Inc. | Key People and Executives
Anastasios E. Gianakakos
President, Chief Executive Officer & Director
David P. Meeker
Independent Director
Wendy L. Yarno
Independent Director
Kimberly J. Popovits
Independent Director
Sunil Agarwal
Independent Director
Mark L. Perry
Lead Independent Director
Mary B. Cranston
Independent Director
Anastasios E. Gianakakos
President, Chief Executive Officer & Director
June Lee
Chief Operating & Development Officer
Taylor C. Harris
Chief Financial Officer
Marc Semigran
Chief Medical Officer
Robert Scott McDowell
Chief Scientific Officer
Jake Bauer
Chief Business Officer
Joseph Lambing
Senior VP-Nonclinical & Pharmaceutical Development
Ingrid Boyes
Senior Vice President-Human Resources
Cynthia J. Ladd
General Counsel
David P. Meeker
Independent Director
Wendy L. Yarno
Independent Director
Kimberly J. Popovits
Independent Director
Sunil Agarwal
Independent Director
Mark L. Perry
Lead Independent Director
Mary B. Cranston
Independent Director
| Address |
333 Allerton Avenue
San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.myokardia.com |
| Updated |
07/08/2019 |
| MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. |
